Introduction {#Sec1}
============

Esophageal carcinoma is the eighth most common type of cancer in the world \[[@CR13]\]. Although the recent rise in incidence of esophageal cancer has predominantly been caused by an increase in adenocarcinomas, the majority of esophageal cancer cases globally are squamous cell carcinomas \[[@CR13]\]. For both histological types, radical en bloc esophagectomy with an extensive lymph node dissection offers the best chance for cure, leading to an overall 5-year survival rate of around 30% \[[@CR1], [@CR20]\].

Well-known histopathological factors for prognostication of esophageal cancer include the TNM stage, the number of positive lymph nodes, and the presence of extracapsular lymph node involvement \[[@CR16], [@CR24], [@CR26], [@CR32]\]. Recently, there has been a growing interest in the prognostic value of molecular markers in (esophageal) cancer \[[@CR21]\]. The expression of such markers is often studied by immunohistochemistry on formalin-fixed, paraffin-embedded tumor slides. Tissue microarray (TMA) technology has been developed to enable high-throughput immunohistochemical analyses \[[@CR14]\]. By inserting small (diameter e.g. 0.6 mm) donor tissue core biopsies into a single recipient paraffin block, this technique allows for rapid analysis of large numbers of tissues under standardized laboratory and evaluation conditions without significantly damaging the patient's tissue. In addition, TMA technology leads to a significant reduction of the amount of consumables used and time needed for interpretation, increasing cost-effectiveness.

A potential disadvantage compared to full tissue sections is that the donor cores may not be representative for the whole tumor, particularly in case of heterogeneous tumors and heterogeneously expressed molecular markers. Hence, some validation studies have been performed in various cancers using different kinds of antibodies \[[@CR2], [@CR4], [@CR6], [@CR7], [@CR9], [@CR12], [@CR23], [@CR35]\]. Although several studies have revealed novel prognostic biomarkers in esophageal squamous cell cancer (ESCC) by means of TMA technology \[[@CR38], [@CR39], [@CR41]\], this technique has not yet been validated for these tumors.

The aim of the present study was, therefore, to validate TMA technology in ESCC by assessing the concurrence of immunohistochemical staining scores of established molecular markers with various expression patterns between triplicate 0.6 mm core biopsies of the TMA and their whole tissue section counterparts.

Materials and methods {#Sec2}
=====================

TMA construction {#Sec3}
----------------

Formalin-fixed, paraffin-embedded tissues from thoracic ESCCs of consecutive patients having undergone esophagolymphadenectomy at the authors' institute between 1989 and 2006 were retrieved from the archives of the Department of Pathology. Patients who received neoadjuvant therapy were excluded from this study. The study was carried out in accordance with the ethical guidelines of our institution concerning informed consent about the use of patient's materials after surgical procedures.

By an experienced pathologist (FtK), three representative tumor regions were marked on one selected hematoxylin and eosin (H&E)-stained section of each tumor, avoiding areas of necrosis. From these three tumor regions, a tissue cylinder with a diameter of 0.6 mm was punched out of the corresponding paraffin block ('donor block') and placed into the TMA paraffin block using a manual tissue arrayer (MTA-I, Beecher Instruments, Sun Prairie, USA), which was guided by the MTABooster® (Alphelys, Plaisir, France). The distribution and position of the cores was determined in advance with the TMA-designer Software (Alphelys-TMA Designer®, Version 1.6.8, Plaisir, France). Cores of normal esophageal mucosa, lymph node, kidney, liver, spleen, and prostate were incorporated in the tissue array block as internal controls.

Immunohistochemistry {#Sec4}
--------------------

For each marker, a 4-μm slide of the TMA and one of every selected donor paraffin block were immunohistochemically stained. Table [1](#Tab1){ref-type="table"} shows the details of all antibodies, dilutions, incubation times and antigen retrieval methods applied in this study. Table 1Specification of antibodies used and details of tissue processingPrimary antibodyStaining patternSource^a^Clone and codeAntigen retrievalDilutionIncubation time (min/room temperature)Detection^b^Positive controlProcedureCK5/6CytoplasmicChemiconD5/16 B4EDTA pH 9.01:3,00060Strept ABCBreastAutostainerCK14CytoplasmicNeomarkersLL002EDTA pH 9.01:40060PowervisionBreastAutostainerE-cadherinMembranousZymed4A2C7Citrate autoclave pH 6.01:20060PowervisionBreastAutostainerMIB-1 (Ki-67)NuclearDakoM7240Citrate pH 6.01:10060Strept ABCTonsilAutostainerp53NuclearBiogenexBP53-12Citrate pH 6.01:20060Strept ABCSerous adenocarcinoma of the endometriumAutostainer^a^Biogenex, San Ramon, CA, USA; Chemicon, Chemicon International, Temecula, CA, USA; Dako, DakoCytomation, Glostrup, Denmark; Neomarkers, Fremont, USA; Zymed, Zymed Laboratories, San Francisco, CA, USA.^b^Strept ABC is biotinylated horse--antimouse Vector BA-2000, diluted 1:500 in PBS, followed by streptavidin--biotin complex, diluted 1:1,000. Powervision ready to use (Poly-HRP-antiMs/Rb/RtIgG biotin-free; ImmunoVision Technologies, Norwell, CA, USA).

For all stainings, sections were deparaffinized in xylene for 10 min followed by dehydration through graded alcohols. Endogenous peroxidase activity was blocked for 15 min in a buffer solution of pH 5.8 (containing 8.32 g citric acid, 21.52 g disodium hydrogen phosphate, 2 g sodium azide in 1 l of water) with hydrogen peroxide (0.3%). After antigen retrieval for 20 min, a cooling down period of 30 min was followed by incubation with the primary antibody. Depending on the antibody used, slides were incubated with the secondary antibody followed by the streptavidin--biotin complex or slides were directly incubated with Powervision (details of both products shown in the legend of Table [1](#Tab1){ref-type="table"}). Then, the peroxidase reactivity was developed by 3,3′-diaminobenzidine for 10 min and slides were counterstained with Mayer's hematoxylin. In between steps, slides were washed with phosphate-buffered saline (pH 7.4).

Immunohistochemical scoring {#Sec5}
---------------------------

By two observers (FtK and JB) conjointly, the degree of differentiation and the percentage of immunohistochemically stained tumor cells were determined in all TMA cores and in the full sections of the selected donor blocks. Histologic grade was scored as well-differentiated (G1), moderately differentiated (G2), or poorly differentiated (G3) \[[@CR37]\]. Staining of p53 and Ki-67 were marked as negative (\<10% of tumor nuclei stained), weakly positive (10--50%), or strongly positive (≥50%) \[[@CR10], [@CR40]\]. Cytokeratin (CK)5/6 and CK14 staining were scored as negative (\<10% of tumor cell cytoplasms stained), weakly positive (10--80%), or strongly positive (≥80%). E-cadherin expression was regarded negative when \<50% of tumor cell membranes stained and positive when ≥50% stained \[[@CR29], [@CR30]\].

Cores were considered lost if \<10% of cells contained tumor ('sampling error') or when \<10% of tissue was present ('absent core'). Cases were excluded if two out of three cores were lost. When the scores between the cores of a particular case differed, the most frequent score determined the overall score. In case of three different scores in one case, the middle score was chosen. When only two cores were available with both a different score, the case was excluded from further analysis \[[@CR11]\].

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using the SPSS software for Windows (Version 12.0, SPSS, Chicago, IL, USA). Sixty-four donor blocks (60% of the tumors incorporated in the TMA) were randomly chosen by means of a random selection function of SPSS.

To determine the chance-corrected agreement between the immunohistochemical staining scores of TMA cores and large sections, the Cohen's weighted kappa statistic was calculated. Chance-corrected agreement was considered poor if *κ* \< 0.00, slight if 0 \< *κ* \< 0.20, fair if 0.21 \< *κ* \< 0.40, moderate if 0.41 \< *κ* \< 0.60, substantial if 0.61 \< *κ* \< 0.80, and almost perfect if 0.81 \< *κ* \< 1.00 \[[@CR17]\]. The overall agreement was defined as the percentage of correct agreement between the TMA and the donor blocks from the total number of cases \[[@CR15]\].

Results {#Sec7}
=======

Of the 324 (3 × 108) tumor tissue cores that were transferred into the TMA paraffin block, a median of 295 (91%) was available for immunohistochemical scoring on the 6 TMA slides used in this study (Table [2](#Tab2){ref-type="table"}). Of the 64 randomly selected cases, a median of 176 (92%) of 192 cores (3 × 64) was evaluable on the TMA slides. Table 2Overview of the amount of cores that were evaluable, absent or contained too little tumor in all 108 cases and in the 64 randomly selected cases on the TMA slides H&ECK5/6CK14E-cadherinKi-67p53MedianTotal TMA cases (*n* = 108) No. of evaluable cores293309294306293295295 Percentage90959194909191 No. of absent cores207229222221 Percentage6273776 No. of cores without tumor11889979 Percentage4333323Randomly selected TMA cases (*n* = 64) No. of evaluable cores176187176185176176176 Percentage92979296929292 No. of absent cores133134131313 Percentage7272777 No. of cores without tumor3233333 Percentage2122222*H&E*: hematoxylin and eosin

On the H&E-stained TMA slide, 49 (76%) of the 64 randomly chosen cases were represented by 3 cores; 14 (22%) by 2 cores. One (1.6%) case was excluded from further analysis because only a single core was available. The agreement in the scores for the grade of differentiation between the TMA cores and the full sections is shown in Table [3](#Tab3){ref-type="table"}. The weighted kappa score was 0.65. Table 3Agreement in the degree of differentiation between TMA cores and full sections Full sectionG1G2G3Total*κ*TMAG12305 G2221225 G3072633 Total43128630.65*G1*: well-differentiated, *G2*: moderately differentiated, *G3*: poorly differentiated

Fifty-nine (92%) of the 64 randomly selected cases stained for CK5/6 were represented by 3 cores (Fig. [1](#Fig1){ref-type="fig"}); the 5 remaining cases by 2 cores. The immunohistochemical scores of the TMA and the donor blocks are shown in Table [4](#Tab4){ref-type="table"}. Overall agreement in CK5/6 scores between the TMA and the donor blocks was 98% with a kappa of 0.93. Fig. 1Example of strong CK5/6 staining in TMA cores and the corresponding full section. **a** Three TMA cores representing one tumor; magnification ×20. **b** Enlargement of the middle TMA core depicted in **a**; magnification ×100. **c** Part of the slide of the donor block of the same tumor; magnification ×100Table 4Agreement in immunohistochemical scores between TMA cores and full slides stained for CK5/6 and CK14 Full sections\<10%10--80%≥80%Total*κ*TMAsCK5/6 \<10%1102 10--80%0404 ≥80%005858 Total1558640.93CK14 \<10%5218 10--80%011213 ≥80%043438 Total51737590.71

For CK14, two cases were excluded because only one tumor core was left and three cases were also excluded because the two available cores had discrepant immunohistochemical scores. Fifty (85%) of 59 cases had complete agreement (Table [4](#Tab4){ref-type="table"}). Four cases were scored one class higher on TMA when compared with the full sections. Conversely, five other cases were classified lower on TMA with one case two classes lower. Kappa score was 0.71.

Regarding E-cadherin staining, three assessable cores were present in 89% of the cases; two cores in 11%. Overall agreement in E-cadherin staining scores was accomplished in 72% of cases (Table [5](#Tab5){ref-type="table"}). In one case, a higher score was found on the TMA compared to the full section. In 17 cases, the expression of E-cadherin was scored lower on TMA than on the full sections. The observed kappa was 0.47. Table 5Agreement in immunohistochemical scores between TMA cores and full slides stained for E-cadherin  Full sectionsE-cadherin\<50%≥50%Total*κ*TMA \<50%221739 ≥50%12425 Total2341640.47

Three-core analysis of Ki-67 staining could be performed in 78% of selected cases and two-core analysis in 19%. Two cases were represented by a single tumor core and were, therefore, excluded from further analysis. Ki-67 staining was scored as "moderate" on both TMA and full sections in 42 (69%) of 61 selected cases. In 79% of cases, the Ki-67 scores of the TMA were similar to that of the full sections. Thirteen cases were discordant (Table [6](#Tab6){ref-type="table"}); kappa was 0.42. Table 6Agreement in immunohistochemical scores between TMA cores and full slides stained for Ki-67 and p53 Full sections\<10%10--50%≥50%Total*κ*TMAsKi-67 \<10%2103 10--50%342348 ≥50%06410 Total5497610.42p53 \<10%193022 10--50%0123 ≥50%033538Total19737630.86

With regard to p53 staining, two cores were present in 12 (19%) cases and 3 cores were available in 51 (80%) cases. One case was excluded as it was represented by only one TMA core. Complete agreement was achieved in 87% of the selected tumors (Table [6](#Tab6){ref-type="table"}). In the eight nonconcordant cases, the difference was one class, resulting in a kappa of 0.86.

Discussion {#Sec8}
==========

After its introduction in 1998, TMA technology has been applied in the immunohistochemical analysis of various malignancies, including squamous cell carcinomas and adenocarcinomas of the esophagus \[[@CR3], [@CR5], [@CR18], [@CR19], [@CR25], [@CR41]\]. Although it seems a very attractive method for high-throughput analysis of hundreds of tissues simultaneously, it may have limitations as the evaluation of the marker expression is reduced from full-section analysis to a few tissue cores of only 0.6 mm in diameter, especially for proteins that are heterogeneously expressed or that are cell cycle-dependent \[[@CR36]\]. It is, therefore, essential to assess in each type of cancer individually and for every molecular marker whether TMA technology is feasible and valid \[[@CR8], [@CR33]\]. To our knowledge, this has not been done in esophageal cancer.

In our TMA containing triplicate cores of 108 ESCCs, a median of 9% of cores was uninformative (6% lost during tissue processing and 3% containing too little tumor), which is comparable to the results reported in other studies \[[@CR7], [@CR8], [@CR27]\]. Improper selection of representative tumor areas on the donor block's H&E slide by the pathologist or incorrect punching of these representative areas out of the donor block can cause tissue cores that contain too little tumor. Possible causes of absent cores are the size and fragility of the tumor tissue used and the aggressiveness of tissue processing applied \[[@CR31], [@CR35], [@CR42]\].

Moreover, the number of available cores on the TMA slide depends on the level at which the TMA paraffin block has been sectioned. The slides stained for H&E, CK14, Ki-67, and p53 were one of the first slides that were cut from our TMA block, whereas sections stained for CK5/6 and E-cadherin were taken slightly deeper. On these latter sections, a lower number of absent cores was observed (Table [2](#Tab2){ref-type="table"}), showing that not all cores were placed at the exact same level in the TMA block during TMA construction, mainly due to dissimilar thicknesses of the donor paraffin blocks that were used to construct the TMA \[[@CR34]\].

The agreement in immunohistochemical results of the markers between our TMA and the full sections varied from moderate to almost perfect (*κ* = 0.42 to 0.93), which is consistent with the results reported in other TMA validation studies \[[@CR4], [@CR7], [@CR8], [@CR31], [@CR35]\]. The observed variation in agreement could be due to tumor heterogeneity, topographical variation in the expression pattern of the molecular marker, or to the scoring criteria used \[[@CR31]\].

Regarding tumor heterogeneity, the optimal amount of tissue cores incorporated in the TMA has been a matter of debate. Several validation studies have shown that three cores are highly representative for the full section \[[@CR6], [@CR11], [@CR12], [@CR28]\]. The addition of a fourth core did not add to the percentage of agreement in a colorectal cancer TMA \[[@CR12]\]. Moreover, the more cores punched per case, the fewer cases can be placed into the TMA reducing throughput. Adding a fourth core may nevertheless be worthwhile in tissues prone to uninformative cores due to small lesions such as dysplasias or carcinomas in situ \[[@CR42]\]. In our TMA, the amount of uninformative cores was low (5--10%), probably because ESCCs have a large diameter, thereby increasing the chance of obtaining a core containing tumor tissue. Taken together, we consider it justified to utilize three biopsy cores in ESCCs. Nonetheless, using such a low amount of cores requires careful selection of the tumor regions by an experienced pathologist to deal with the heterogeneity of the tumor in the TMA \[[@CR33]\].

The agreement between TMA and full sections was substantial to almost perfect for CK5/6 and CK14. Because 91% of cases have shown a very strong expression of CK5/6 and only 1 of 64 cases showed negative staining, this molecular marker does not subdivide ESCCs and consequently will not be a prognostic marker for this malignancy. CK14 was more evenly distributed over the three scoring groups, but because one case was scored two classes lower on TMA when compared to the full section, kappa was lower when compared to CK5/6.

The relatively moderate concordance in case of Ki-67 may be explained by the fact that almost 80% of cases were situated in one category (staining of 10--50% of tumor cells) with 13 discordant cases deviating from this category. E-cadherin also had a moderate concordance, mainly because the relatively faint staining intensity of this molecular maker made its assessment in our TMA very difficult (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Representative example of E-cadherin staining in TMA cores and the corresponding full section. **a** Three TMA cores representing one tumor; magnification ×20. **b** Enlargement of the right TMA core depicted in **a**; magnification ×100. **c** Part of the slide of the donor block of the same tumor; magnification ×100

TMA technology was also found to be valid for determining the histologic grade of differentiation in ESCC. Complete agreement between TMA and full sections occurred in 78% (49 out of 63; *κ* = 0.65) of selected cases, which is high when compared to the 40% agreement achieved in a TMA of bladder cancer \[[@CR22]\]. Due to its homogeneous staining pattern, p53 showed excellent concordance (*κ* = 0.86) in our microarray (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Representative example of p53 staining in TMA cores and the corresponding full section. **a** Three TMA cores representing one tumor; magnification ×20. **b** Enlargement of the left TMA core depicted in **a**; magnification ×100. **c** Part of the slide of the donor block of the same tumor; magnification ×100

The concurrence between the TMA and the full sections is affected by the cut-off values of the immunohistochemical scoring system of the stainings as well \[[@CR7], [@CR31]\]. The application of a two-class scoring system in an endometrial cancer TMA improved *κ* to 1.0 compared to 0.81 with a three-class system \[[@CR7]\]. In our study, the two-class scoring system did not substantially affect the kappa (data not shown). Because the E-cadherin expression had a very low intensity in our ESCCs, we have chosen to apply a two-class system. In addition, the cut-off values indicating a strong immunohistochemical expression were set higher in the cytokeratins (80%) than in the other molecular markers (cut-off value 50%) because otherwise practically all tumors would be designated having a strong expression of cytokeratins.

Now that our esophageal cancer TMA has been validated, it will be used to correlate the expression of various molecular pathways with clinicopathologic data, aiming at detecting markers of prognostic significance and molecular targets for new therapies. Because the agreement between TMA slides and full sections depended on the molecular marker stained for, it should be considered to assess the expression pattern of a marker on a full section first, before staining a TMA slide. When a focal or heterogeneous expression pattern is noticed, it might be more valuable to assess marker expression by means of full sections instead of TMA. On the other hand, when a marker shows a homogeneously diffuse expression pattern, staining a TMA slide does allow for high-throughput screening of tumors. When a prognostic molecular marker has been identified by means of TMA technology, it is recommended to verify the results by full-section analysis.

In conclusion, this study has demonstrated TMA technology to be a valid method for immunohistochemical analysis in ESCC with agreement levels for well-known molecular markers with different staining potential between TMA and full sections ranging from moderate to almost perfect.
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